Actively Recruiting
Evaluating Imaging Methods for Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole Body MRI
Led by European Institute of Oncology · Updated on 2024-03-20
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing whole body MRI WB-MRI with Bone Scintigraphy BS and Computerized Tomography CT scans in men with metastatic castration-resistant prostate cancer that has spread to the bone. This prospective observational study aims to evaluate these imaging methods while patients receive standard treatments such as hormonal therapy, chemotherapy, radium-223, bisphosphonates, denosumab, or supportive care. The study is conducted at a single center and does not change the treatments patients receive. Patients will undergo CT, BS, and WB-MRI imaging at the start of the study and every 12 weeks up to week 96. After this, imaging will occur every 24 weeks until disease progression or week 192. Treatment choices, dosing, schedules, and monitoring are decided by the treating clinicians. Radiotherapy is allowed with communication to avoid affecting imaging interpretation. Questionnaires about imaging preferences will be collected at baseline, week 36, and study end. Participants will have routine clinical and physical examinations throughout the study. Radiologists reading the WB-MRI scans will not know the CT and BS results, and vice versa, to reduce bias. The main outcome measured is the time to disease progression in bone metastases identified by WB-MRI over 192 weeks. The total duration of participant involvement can be up to nearly four years, with ongoing imaging and assessments throughout.
CONDITIONS
Brief Title
Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone
Research Team
G
Giuseppe Petralia, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here